Relapsed/Refractory Leukemias

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
SGI-1776Phase 11 trial
Active Trials
NCT01239108WithdrawnEst. Apr 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astex PharmaceuticalsSGI-1776

Clinical Trials (1)

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Start: Oct 2010Est. completion: Apr 2012
Phase 1Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space